Faruqi and Faruqui, LLP Logo
Share this page

Insys Therapeutics, Inc. (INSY)

NASDAQ:INSY

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Insys Therapeutics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insys Therapeutics, Inc. (“Insys” or the “Company”) (NASDAQ:INSY).

On October 26, 2017, the U.S. Department of Justice announced that John N. Kapoor, the Company’s co-founder and majority owner, “was arrested this morning in Arizona and charged with RICO conspiracy, as well as other felonies, including conspiracy to commit mail and wire fraud and conspiracy to violate the Anti-Kickback Law.”

Specifically, the superseding indictment alleges that Kapoor and several other of Insys’ former officers “conspired to bribe practitioners in various states […] in order to get them to prescribe a fentanyl-based pain medication.” The medication in question, Subsys, “is a powerful narcotic intended to treat cancer patients suffering intense breakthrough pain.”

Following this announcement, Insys’ share price declined significantly.

If you invested in Insys stock or options and would like to discuss your legal rights, please fill out the form below.  There is no cost or obligation to you.  You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Insys Therapeutics, Inc. (INSY)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 10/26/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.